Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) have received a consensus rating of “Moderate Buy” from the eight brokerages that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $66.6667.

Several equities analysts recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating and set a $80.00 price objective on shares of Reviva Pharmaceuticals in a report on Tuesday, December 23rd. Chardan Capital reissued a “buy” rating and issued a $40.00 price objective on shares of Reviva Pharmaceuticals in a research note on Monday, January 5th. D. Boral Capital downgraded shares of Reviva Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, March 5th. Wall Street Zen raised shares of Reviva Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, December 27th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a research report on Thursday, January 22nd.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in RVPH. Geode Capital Management LLC boosted its stake in shares of Reviva Pharmaceuticals by 6.9% during the 2nd quarter. Geode Capital Management LLC now owns 448,202 shares of the company’s stock worth $171,000 after purchasing an additional 29,063 shares during the last quarter. NewEdge Advisors LLC purchased a new stake in shares of Reviva Pharmaceuticals during the first quarter worth about $58,000. XTX Topco Ltd raised its position in shares of Reviva Pharmaceuticals by 63.6% in the fourth quarter. XTX Topco Ltd now owns 164,291 shares of the company’s stock valued at $46,000 after buying an additional 63,893 shares during the last quarter. Lido Advisors LLC acquired a new position in shares of Reviva Pharmaceuticals in the third quarter valued at approximately $37,000. Finally, Millennium Management LLC lifted its stake in shares of Reviva Pharmaceuticals by 15.0% during the third quarter. Millennium Management LLC now owns 1,711,221 shares of the company’s stock valued at $631,000 after buying an additional 223,178 shares during the period. Institutional investors and hedge funds own 63.18% of the company’s stock.

Reviva Pharmaceuticals Trading Up 7.7%

RVPH stock opened at $2.81 on Thursday. The firm has a 50 day moving average of $5.53 and a 200-day moving average of $8.57. The company has a market cap of $16.42 million, a price-to-earnings ratio of -0.31 and a beta of 0.10. Reviva Pharmaceuticals has a 12-month low of $2.57 and a 12-month high of $24.50.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.